Product Overview

Alternative Name: Nestorone (NES) + Estradiol (E2) Transdermal Gel

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Transdermal

Duration Type: Short-acting

Description: Proprietary gel technology (Antares ATD™ technology) of a hydroalcoholic gel combined with permeation enhancers to deliver Nestorone and Estradiol through the skin. The gel is administered by an airless, pre-filled metered dose pump dispenser.

Updated date: May 30, 2018

Vertical Tabs


Project Phase: Late Development

Project Stage: Phase II

Status Details:
  • Phase 1 and 2 clinical trials have been conducted in Chile, the Dominican Republic, and the USA. An Investigational New Drug (IND) application was submitted to the FDA in 2008, and outcomes from the dose-finding study were used to support registration of a new patent.

Download Product Report